Current Pharmaceutical Design

William A. Banks  
Building 1, Room 810A
1600 S. Columbian Way
Seattle, WA 98108


Histone Deacetylase Inhibitors and Neurodegenerative Disorders: Holding the Promise

Author(s): Antonello Mai, Dante Rotili, Sergio Valente and Aleksey G. Kazantsev

Affiliation: Pasteur Institute - Cenci- Bolognetti Foundation, Department of Drug Chemistry and Technologies, University of Rome “La Sapienza”, P. le A. Moro, 5, 00185, Rome, Italy.


Neurodegenerative disorders (NDs) such as Huntingtons disease, Alzheimers disease, Parkinson disease, amyotrophic lateral sclerosis, spinal muscular atrophy, Friedreichs ataxia, and others are multi-factorial illnesses, in which many pathways (still poorly understood) act serially and in parallel to give a determined pathologic phenotype. Thus, presently there are no effective cures for these diseases. Some phenotypic as well as mechanistic features, common to the most of NDs, can be linked to epigenetic defects, that can lead to alteration of acetylation homeostasis and impairment of the histone acetyltransferase (HAT): histone deacetylase (HDAC) balance. Here we survey most of the recent applications of HDAC inhibitors in the cited NDs, and we make the point of our (up to now) knowledge about the involvement of singular HDAC/SIRT isoform in NDs and other CNS pathologies.

Keywords: Epigenetics, HDAC inhibitors, neurodegenerative disorders, Huntington's disease, Alzheimer's disease, Parkinson disease, amyotrophic lateral sclerosis, spinal muscular atrophy, Friedreich's ataxia

Order Reprints Order Eprints Rights & PermissionsPrintExport

Article Details

Page: [3940 - 3957]
Pages: 18
DOI: 10.2174/138161209789649349
Price: $58